Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule
about
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma ModelMonoclonal antibodies in the treatment of multiple myeloma: current status and future perspectivesTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyExtracellular Antibody Drug Conjugates Exploiting the Proximity of Two ProteinsCD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer.Enrichment of human hematopoietic stem/progenitor cells facilitates transduction for stem cell gene therapy.Nicotinamide phosphoribosyltransferase in malignancy: a review.CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFNγ cytokines and proliferation.Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche.New targets for antibody therapy of pediatric B cell lymphomas.Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development.Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.Novel investigational drugs active as single agents in multiple myeloma.Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.CD38 expression in early B-cell precursors contributes to extracellular signal-regulated kinase-mediated apoptosis.Antibody mimicry, receptors and clinical applications.SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formationCD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions.Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients.Protein-complex structure completion using IPCAS (Iterative Protein Crystal structure Automatic Solution).Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?Hepatoma-Targeted Radionuclide Immune Albumin Nanospheres: (131)I-antiAFPMcAb-GCV-BSA-NPs.CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
P2860
Q26782214-D2D27A19-DD0E-412A-8669-FC220FF866C7Q26799104-4375293D-BC6B-42CB-B9D7-9F12DF8F0C1BQ26993238-BB919201-369C-4617-8DD0-F7108B87F25DQ36081864-0D655690-0506-4FEC-9652-D4D0A7D885D0Q36118086-29F700D9-E40E-4CEB-81D1-C721F58FA3C4Q37358032-C652B600-3619-438B-A139-D13BA8685525Q37424391-E224762C-08F7-4722-B9C7-6554B2AA453BQ37483026-E8EA531F-A6DA-4A17-B95A-CC3B587E9675Q38232436-1FF05985-4580-4A36-8A21-60A59E958DF8Q38242984-930FC6BB-968F-4F93-8C36-BEBF6B4CA847Q38542091-3F88B2F5-D861-4FE7-A94A-8008310471B9Q38601582-F7436100-4DC0-40A1-89DD-12EA2F76F8DCQ38690290-4E92BDCD-99BD-4FF8-99E9-20FB94DDC32BQ38764001-801EA9B9-61B5-4D75-9D80-37604AF3FEEFQ38817467-832B2C6D-1E73-434F-9067-C187604D464CQ38962978-0990CA24-5B4C-4BA9-85F1-57D6FE47C263Q39062940-7F54B11F-DCB8-4730-81EA-A359EB6A3D1DQ40575818-B5320B1B-9897-4B35-A9AE-FF0597248430Q41345636-102E611A-56B8-485C-8FFB-1CD058C15B84Q46360856-1337642D-5519-4900-8512-F2F47AE7F756Q47571295-62BBC4C2-E805-4F71-B147-2EF7F57501FAQ47660573-3219105D-E96A-48E4-AD0D-5E44FF2ED2DFQ52644017-1DFEE181-4129-45C3-B4A6-2AA962314CD6Q53631904-C6FA5439-BA9A-4BC6-8012-08AE4AAFE535Q55021985-B2D3A627-1F3A-45E4-A83D-89B738F706B7Q55190863-E22F25CA-1394-4290-9A08-654DC0997CBDQ57191729-DFD3168B-7FD7-47BC-B564-9B169DFA486E
P2860
Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Anti-CD38 antibody therapy: wi ...... ristics of the target molecule
@ast
Anti-CD38 antibody therapy: wi ...... ristics of the target molecule
@en
Anti-CD38 antibody therapy: wi ...... ristics of the target molecule
@nl
type
label
Anti-CD38 antibody therapy: wi ...... ristics of the target molecule
@ast
Anti-CD38 antibody therapy: wi ...... ristics of the target molecule
@en
Anti-CD38 antibody therapy: wi ...... ristics of the target molecule
@nl
prefLabel
Anti-CD38 antibody therapy: wi ...... ristics of the target molecule
@ast
Anti-CD38 antibody therapy: wi ...... ristics of the target molecule
@en
Anti-CD38 antibody therapy: wi ...... ristics of the target molecule
@nl
P2093
P2860
P50
P1433
P1476
Anti-CD38 antibody therapy: wi ...... ristics of the target molecule
@en
P2093
Alberto L Horenstein
Chiara Ghimenti
Gianluca Zaccarello
Valeria Quarona
P2860
P2888
P304
P356
10.2119/MOLMED.2013.00009
P407
P577
2013-05-20T00:00:00Z
P5875
P6179
1068965599